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Parvoviruses
PARV4/5 in
Hepatitis C Virus–
infected Persons 
To the Editor: Parvoviruses are
small, nonenveloped DNA viruses
that infect both vertebrate and inverte-
brate hosts. Until recently, parvovirus
B19 and adeno-associated viruses,
which belong to the genera
Erythrovirus and  Dependovirus,
respectively, were the only known
members of the family Parvoviridae
that infected humans (1). However, 2
recent publications have identified 2
distinct, novel parvoviruses in
humans by using the DNase
sequence–independent single-primer
amplification technique and a related
method (2,3). The first of these virus-
es, termed PARV4, was observed in a
patient with symptoms of acute viral
infection syndrome after high-risk
behavior for infection with HIV-1,
although the patient was subsequently
confirmed as negative for HIV-1 (2).
The second parvovirus was identified
in respiratory samples from children
with lower respiratory tract infections
and termed human bocavirus (3).
Parvovirus B19 is a frequent con-
taminant of plasma pools that are used
in the manufacture of blood products,
which results in high viral loads in
pools and viral transmission in recipi-
ents of clotting factors (4). We identi-
fied PARV4 in such pools (5), albeit at
a lower frequency and titer than par-
vovirus B19, when parvovirus B19
was not excluded by screening with
nucleic acid amplification techniques.
Sequence analysis identified a second
genotype of PARV4, which we have
termed PARV5, that shares 92%
nucleotide identity with PARV4 (5).
PARV4 was originally identified
in a plasma sample from a homeless,
injection drug user with fatigue, night
sweats, pharyngitis, neck stiffness,
vomiting, diarrhea, arthralgia, and
confusion (2). This person was coin-
fected with hepatitis B virus. In this
study, we looked retrospectively for
PARV4 and PARV5 in blood samples
from a similar cohort of persons,
many of whom were known to be
infected with hepatitis C virus (HCV)
(as determined by the presence of
both HCV RNA and antibodies to
HCV), and some of whom were intra-
venous drug users (IVDUs) (6).
Blood samples were collected
from 26 cadavers in London and the
surrounding area as part of a study to
investigate the inhibition of nucleic
acid amplification techniques for
bloodborne viruses in tissue samples
(6). The cohort was composed of 10
HCV RNA–positive IVDUs, 8 HCV
RNA–positive non-IVDUs, 4 HCV
RNA–negative IVDUs, and 4 HCV
RNA–negative non-IVDUs (Table).
Nucleic acid was extracted as previ-
ously described (4) by using the
MagNA Pure LC instrument (Roche,
Basel, Switzerland). PCR was per-
formed with primers specific for the
second open reading frame (ORF2) in
the PARV4 genome (2), which is
homologous to the VP1 capsid of par-
vovirus B19. Primers PVORF2F (5′-
AGGAGCAGCAAACAAACTCA-
GAC-3′) and PVORF2R (5′-TCCTT-
CATCGCGGCTGTCACTAA-3′)
amplify a 268-bp region of ORF2
(nucleotides 2710–2977, GenBank
accession no. AY622943). The PCRs
were performed and analyzed as pre-
viously described (5). The assay is
highly specific (no cross-reactivity
with parvovirus B19) and sensitive
(detects 5–10 copies of PARV4 virus
DNA per reaction). 
PCR products were cloned,
sequenced, and compared with the
prototype PARV4. Two blood samples
were positive for PARV4, and a third
sample was positive for PARV5, with
99%–100% nucleotide identity. These
positive samples were from HCV
RNA–positive IVDUs (Table). The
titer of PARV4 and PARV5 DNA in
the positive samples was low and did
not exceed >700 copies/mL of plas-
ma, as determined by using a consen-
sus TaqMan assay (J. Fryer, unpub.
data). None of the other blood sam-
ples tested was positive for PARV4
and PARV5, including those for per-
sons who were HCV RNA negative
and not IVDUs.
In our previous study (5) of >130
fractionation pools (composed of
thousands of units from screened
healthy donors) for PARV4, the only
positive pools were from North
America and no European pools were
positive for PARV4 or PARV5. These
viruses may be present in such pools
but diluted to undetectable levels. In
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the present study, PARV4 and PARV5
have been identified in blood samples
obtained from persons from the United
Kingdom. For parvovirus B19, there is
evidence of persistent virus infection,
at low levels, in bone marrow of previ-
ously exposed persons (7) and in plas-
ma of immunocompromised and
immunocompetent persons (8,9).
There is also evidence for the lifelong
persistence of parvovirus B19 (geno-
types 1 and 2) in tissues such as skin
and synovia (10). PARV4 and PARV5
virus genomes share only limited
homology with parvovirus B19 (<30%
amino acid similarity). Although they
have been detected in blood and plas-
ma, nothing is known about the role of
these viruses in human disease or their
ability to persist in infected persons,
healthy or otherwise. Further studies
will be required to determine the
prevalence of PARV4 and PARV5 in
healthy persons compared with its
prevalence in those with chronic infec-
tions and at high risk, such as IVDUs,
and to investigate the nature of persist-
ence of these novel viruses.
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Saint Louis
Encephalitis Virus,
Brazil 
To the Editor: Saint Louis
encephalitis virus (SLEV), a member
of the Flaviviridae family, is widely
dispersed in the Americas (1,2). In
Brazil, SLEV was first isolated in the
1960s from a pool of mosquitoes at the
Amazon Basin. Subsequently, the
virus was repeatedly isolated from ani-
mals and arthropods in the Amazon
region and São Paulo state (3).
Nonetheless, isolation of SLEV from
humans is rare; only 2 isolates from
humans were described before 2005.
Each isolate was from a patient who
had jaundice and febrile illness with-
out any neurologic symptoms (1,3).
Recently in São Paulo, SLEV was iso-
lated from a patient who had an incor-
rect diagnosis of dengue fever (2,4).
Despite the rare isolation of
SLEV from humans, antibodies to this
virus have been found in ≈5% of stud-
ied populations in the north and
southeast regions of Brazil. However,
because of antibody cross-reactivity
among different flaviviruses and the
fact that this population is vaccinated
against yellow fever and exposed to
dengue virus (DENV), such results
should be interpreted carefully.
Nevertheless, in these areas, SLEV
may circulate and infect humans,
although most infections are undiag-
nosed (1,3,5).
In contrast to previous instances
in which the disease was detected in
only 1 patient, we describe the first
community outbreak of SLEV in
Brazil. The outbreak was detected in
São José do Rio Preto (population
400,000), in northwest São Paulo
state. This outbreak was concurrent
with a large outbreak of DENV
serotype 3 (DENV-3), which occurred
during the first half of 2006, with
>15,000 possible cases reported to
public health authorities. During this
time, we were involved in an epidemi-
ologic study to monitor the disease.
We tested ≈250 samples for DENV,
and 65% were positive. We tested for
SLEVonly those patients who were in
our hospital or those who were
referred to us for SLEV testing after
an initial diagnosis of SLEV or
DENV. The protocol approved by our
ethical committee allowed us to test
only samples from these patients
(process no. 300/2004).